Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Tina Tan


London, UK
Since she began covering the medtech industry in the late 1990s, Tina Tan has seen significant changes in the industry landscape: companies bulking up to become sector heavyweights, unwieldy conglomerates restructuring to get leaner, new players with game-changing technologies growing and thriving, struggling firms sadly fizzling into oblivion. She has also witnessed how the ever-evolving healthcare environment has impacted the way medical device companies operate, inciting them to develop new technologies – and services – to meet the needs of patient, physician and, of courses, the healthcare payer. As Editor, and prior to that Business Editor, of Clinica Medtech Intelligence, it is Tina’s experience and understanding of the key issues affecting medical device companies that has enabled her to maintain the high quality, business-critical content of Clinica for which the product is recognized globally. Tina has also dabbled in other sectors outside of medtech, having written for an eyewear fashion and an alternative health publication. But as attractive as it was to get cost-price Armani frames and free samples of organic root vegetables, Tina found herself being drawn back to the excitement of the medtech sector. Like many of her long-time colleagues covering this beat, she still marvels at the incredible gizmos and gadgets that are coming out from the industry, especially from the start-ups, and the genius creativity behind these potentially life-saving technologies.  
Set Alert for Articles By Tina Tan

Latest From Tina Tan

DePuy Synthes Builds Out Trauma Offering With TRS' 3D-Printed Tech

Underlining its focus on 3D-printing and the potential this technology can bring, DePuy Synthes has acquired the 3D-printed scaffold platform of Tissue Regeneration Systems, enabling the orthopedics leader to develop patient-specific trauma products in-house.

Orthopedics M & A

Cardinal Health, Medtronic Tie Up $6.1bn Lower-Margin Assets Deal

Medtronic is selling certain lower-margin, lower growth assets within its Patient Monitoring and Recovery division to Cardinal Health in a $6.1bn deal. While the deal may benefit Medtronic's debt situation, the same cannot be said for the buyer.

M & A Deals

Imanova Seeks More Partners For Imaging-Aided Fight Against Neurodegen Disease

With another fresh injection of funds from the UK Medical Research Council, imaging services provider Imanova is advancing to the next stage of its MIND-MAPS program that aims to identify novel early markers of progression of neurodegenerative diseases, including Alzheimer's and Parkinson's. The data generated from the program could be used to help Imanova's pharma partners develop new therapies to tackle these diseases.

Neurology Diagnostic Imaging

HiberGene Casts Net Wide For Series B Funding

From crowdfunding to taking on its distributor partner as investor, the varied fundraising routes that HiberGene traveled down for its series B round has enabled the Irish rapid molecular diagnostic test developer to raise €6.7m.

In Vitro Diagnostics Infectious Diseases

View Of The IVD Horizon: How Roche Diagnostics Sees The Sector Evolving

While the in vitro diagnostics landscape has seen players come and go, Roche Diagnostics has remained at the top. But the Swiss giant, like all its other smaller rivals, is facing a new reality, with increasing pressures to prove medical value, and a more stringent regulatory environment. Medtech Insight spoke to Roche Diagnostics' Jean-Claude Gottraux, head of centralized and point of care solutions, and Jean-Jacques Palombo, lifecycle leader for the company's cardiac, women's health and personalized health care solutions immunoassay portfolio, to gain their perspectives on how the sector has evolved and will continue to evolve. They also spoke about the company's strategy to address these changes and challenges.

In Vitro Diagnostics Business Strategies

VC Deals Analysis: Big Boost From Bumper Round

It had been a slow start to the year but one unusually large financing round from cancer diagnostics company Grail means the first quarter of 2017 has now outpaced the performance from any in the previous four years.

StartUps and SMEs Financing
See All